The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Thomas Liebmann
Project Title: Validation of quantitative virtual microscopy as a novel tool for early detection of neurodegeneration and Alzheimer’s disease from magnetic resonance imaging data
Date: [153]
Request ID: D1707
Aim 1: Establish diagnosis accuracy on confirmed Alzheimer’s disease patient MRI scans using quantitative virtual microscopy
Aim 2: Establish early detection accuracy for discriminating pre-symptomatic degeneration from non-degenerating healthy individuals using quantitative virtual microscopy analysis on MRI scans
Aim 3:
Aim 4:
Investigator: Anne Fagan
Project Title: Roche Elecsys automated CSF assay for Ab42, tau and ptau181
Date: [153]
Request ID: D1706
Aim 1: Evaluate the correspondence between CSF Elecsys data and amyloid PET
Aim 2: Evaluate the ability of CSF Elecsys data to predict cognitive decline
Aim 3: Evaluate the ability of CSF Elecsys data to discriminate clinical groups
Aim 4: Evaluate the analytical performance between Elecsys and INNOTEST CSF data
Investigator: Catherine roe
Project Title: Preliminary data for Mike Wiener project on behalf of JCM
Date: [153]
Request ID: D1705
Aim 1: To compare ability of AD8 and CDR to predict AD dementia
Aim 2:
Aim 3:
Aim 4:
Investigator: Jee-young Han
Project Title: Clinical outcomes and its predictors in CDR 0.5, uncertain dementia
Date: [153]
Request ID: D1704
Aim 1: To define and differentiate clinical characteristics of CDR 0.5, uncertain dementia
Aim 2: To demonstrate the clinical outcomes of CDR 0.5, uncertain dementia
Aim 3: To determine predictors of progression of CDR 0.5, uncertain dementia to AD
Aim 4:
Investigator: Arnaud Charil
Project Title: Potential usage of diffusion basis spectrum imaging (DBSI) to assess white matter inflammation in Alzheimer�s disease
Date: [153]
Request ID: D1703
Aim 1: Generate a normative profile (across brain regions/tracts and subjects) of DBSI parameters, suitable for expressing (defining) �abnormal� levels of these parameters
Aim 2: Explore the profile of abnormalities in the different DBSI parameters in more advanced NIA-AA stage individuals
Aim 3: Refine potential analysis strategies for application to clinical trials
Aim 4:
Investigator: Sergey Shcherbinin
Project Title: Potential usage of PET-based perfusion measurements as candidates neurodegeneration biomarkers
Date: [153]
Request ID: D1702
Aim 1: Analyze dynamic PET images obtained using different radiotracers
Aim 2: Optimize time window to measure perfusion using PET tracers
Aim 3: Perform cross-sectional and longitudinal comparison between perfusion measures and other biomarkers/scores
Aim 4:
Investigator: Samantha Allison
Project Title: Relationship between proton pump inhibitors and risk of dementia, cognition, brain structure, and Alzheimer disease biomarkers
Date: [153]
Request ID: D1701
Aim 1: Examine the relationship between proton pump inhibitors and both risk of dementia and longitudinal change in cognition.
Aim 2: Examine the relationship between proton pump inhibitors and biological markers of Alzheimer disease (e.g., regional based brain volumes obtained via structural MRI, amyloid PET, and CSF biomarkers).
Aim 3:
Aim 4:
Investigator: Chengjie Xiong
Project Title: Pre-Clinical BioMarker Study
Date: [153]
Request ID: D1628
Aim 1: Integrate biomarkers and clinical and cognitive databases from 4 sites and develop novel statistical methods for analyzing biomarkers.
Aim 2: Statistically validate the preclinical stages of AD as proposed by the National Institute on Aging�Alzheimer’s Association (NIA-AA) Workgroup (Sperling et al. 2011).
Aim 3: Optimize the design of modern randomized clinical trials (RCTs) in preclinical or early-stage AD by identifying the cognitive composite that minimizes the sample sizes required to adequately power such trials.
Aim 4: Assess how MRI white matter hyperintensities, infarcts, microbleeds, Body Mass Index (BMI) & HbA1c contribute to the preclinical changes in biomarkers and cognition, and further neuropathologically validate findings of Aim 1 & 2.
Investigator: Joshua Shimony
Project Title: Improved statistical methods for resting state fMRI analysis
Date: [153]
Request ID: D1627
Aim 1: Confirm the utility of new statistical techniques applied to resting state analysis and confirming these methods by comparing resting state connectivity across different ADRC cohorts.
Aim 2:
Aim 3:
Aim 4:
Investigator: Chengjie Xiong
Project Title: Cross-sectional and Longitudinal Comparison of DIAN MC and those in the ACS on Biomarkers and Cognitions when Baseline Ages are Matched
Date: [153]
Request ID: D1626
Aim 1: To compare DIAN MC to those with a positive family history in the ACS on baseline Biomarkers and Cognitions when their age were matched;
Aim 2: To compare DIAN MC to those with a positive family history in the ACS on the longitudinal rates of changes in Biomarkers and Cognitions when their baseline age were matched;
Aim 3:
Aim 4: